The trial involved RR-MS patients who were randomly divided into three groups to receive a 96-week course of interferon beta 1a (IFN-β1) plus a placebo or 20 or 40 μg of ethinyl estradiol. The gene discussed is IFNB1; the disease is myeloid sarcoma.